Transplant Registry Unified Management Program – Page 5

Trump’s Second Term: Mifepristone Battle Looms as Early Test of Abortion Stance

6 months ago talkbio0Tagged court, mifepristone, Reproduction, Supreme, Transplant Registry Unified Management Program, United States Food and Drug Administration, Unspecified Abortion

Mifepristone, abortion, Trump, second term, reproductive rights, FDA, Supreme Court

Trump Withdraws US from World Health Organization, Sparking Concerns Over Global Health Security

6 months ago talkbio0Tagged Communicable Diseases, COVID19 (disease), Generalized, health security, Pandemics, public health medicine (field), Transplant Registry Unified Management Program, WHO, Withdraw (activity), World Health Organization

Trump, World Health Organization, WHO, withdrawal, global health security, infectious diseases, pandemics, COVID-19, public health experts.

Understanding the Second Round of Medicare Drug Price Negotiations: What Trump’s CMS Can and Can’t Change

6 months ago talkbio0Tagged Administration occupational activities, CMS, drug price, Inflation, Medicare, Myasthenic Syndromes, Congenital, negotiation, Prices, Transplant Registry Unified Management Program

Medicare drug price negotiation, Trump administration, CMS, Inflation Reduction Act, drug prices, negotiation process

Biotech Industry Prepares for Trump 2.0: Regulatory Changes and M&A Activity Expected

7 months ago talkbio0Tagged biotech industry, Changing, Drug Industry, Health Policy, M&A activity, regulatory environment, Transplant Registry Unified Management Program, United States Food and Drug Administration

Biotech industry, Trump 2.0, FDA changes, M&A activity, regulatory environment, pharmaceutical industry, healthcare policy

Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns

8 months ago talkbio0Tagged Acquisitions, Administration occupational activities, Biopharma, Independence, Inflation, mergers, Policy, Transplant Registry Unified Management Program, United States Food and Drug Administration, Vaccines

Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act

Controversial Stanford Professor Jay Bhattacharya Nominated by Trump to Lead NIH Amid Criticism Over Pandemic Views

8 months ago talkbio0Tagged Administration occupational activities, Appointments, Bhattacharya, Controversial, COVID19 (disease), Critic, Jay, NIH Director Nomination, Pandemic Response, Professor, Public Health Research, Stanford University, Transplant Registry Unified Management Program

Jay Bhattacharya, NIH Director Nomination, COVID-19 Pandemic Response Critic, Stanford University Professor, Trump Administration, Public Health Research, Controversial Appointment

Trump’s NIH Leadership Plans: From Jay Bhattacharya to a More Traditional Pick?

8 months ago talkbio0Tagged Bhattacharya, Biomedical Research, Jay, Leadership, NIH Mouse, Speed, Transplant Registry Unified Management Program, VWA1 gene

Trump, NIH, Jay Bhattacharya, Warp Speed, Leadership, Biomedical Research

Trump Nominates Surgeon Martin Makary for FDA Commissioner Amid Criticism of COVID Mandates

8 months ago talkbio0Tagged COVID, Makary, mandates, Martin, nomination, Surgeon, Transplant Registry Unified Management Program, United States Food and Drug Administration

Trump, FDA, Martin Makary, COVID mandates, surgeon, nomination

Dr. Mehmet Oz Nominated to Lead Centers for Medicare and Medicaid Services

8 months ago talkbio0Tagged Dr., healthcare leadership, Medicaid, Medicaid Services, Medicare, nomination, ounce, Transplant Registry Unified Management Program

Dr. Mehmet Oz, Medicare, Medicaid, Centers for Medicare and Medicaid Services, Trump nomination, healthcare leadership

RFK Jr.’s HHS Nomination: A Potential Threat to the Biopharma Industry

8 months ago talkbio0Tagged Administration occupational activities, Biopharma, CHARGE Syndrome, Health Policy, Industry, nomination, RFK Jr., Skepticism, Transplant Registry Unified Management Program, Vaccines

RFK Jr., HHS nomination, biopharma industry, vaccine skepticism, health policies, Trump administration